News

A groundbreaking study from the University of Arizona suggests that pyrvinium pamoate, a drug originally designed for pinworm ...
Nebraska Medicine is known for the comprehensive care that it provides. Now, it and the University of Nebraska Medical Center are nationally recognized for something a little bit different ...
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...
A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it means for diabetes.
Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson's disease and a way to modify it, paving the way for future ...
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of ...
Elden Ring Nightreign is adding its next enhanced Everdark Sovereign boss into the game. Fulghor, Champion of the Nightglow will be the next Nightlord to get an enhanced version, arriving on June 26.
Both patients were teenage boys who passed away after developing acute liver failure within two months after treatment with Sarepta’s one-time therapy.
CHICAGO — Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and sustained reductions in body weight compared with placebo ...
PENSACOLA, Fla. -- Change is coming to the way people with mental illness are addressed within the criminal justice system.
Under the auspices of the National Academies of Sciences, Engineering, and Medicine, an ad hoc committee will conduct a study to assess the current evidence base for treatment of Lyme ...
Learn about Lyme disease treatment options, how the condition is managed, recovery expectations, and when to seek further medical care.